CompletedPHASE1, PHASE2NCT02960230
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Studying Diffuse intrinsic pontine glioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Sabine Mueller, MD, PhD, MASUniversity of California, San Francisco
- Intervention
- K27M peptide(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 3-21 years · All sexes
- Timeline
- 2016 – 2023
Study locations (15)
- Rady Children's Hospital-San Diego, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
- St. Louis Children's Hospital, St Louis, Missouri, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- Texas Children's Hospital, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- Seattle Children's Hospital, Seattle, Washington, United States
- The University Children's Hospital in Zurich, Zurich, Canton of Zurich, Switzerland
Collaborators
The V Foundation for Cancer Research · Pacific Pediatric Neuro-Oncology Consortium · Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02960230 on ClinicalTrials.govOther trials for Diffuse intrinsic pontine glioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07076498Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care RadiationM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07501156H3K27M-specific Immune Effector Cells Targeting DMG/DIPGShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06838676ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade GliomasNationwide Children's Hospital
- RECRUITINGPHASE1NCT06305910CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young AdultsOX2 Therapeutics
- RECRUITINGPHASE1NCT06221553Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPGChulalongkorn University
- RECRUITINGPHASE1NCT05544526CAR T Cells to Target GD2 for DMGUniversity College, London
- RECRUITINGPHASE1NCT05762419FUS Etoposide for DMGColumbia University
- ACTIVE NOT RECRUITINGPHASE1NCT05768880Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System TumorsSeattle Children's Hospital